Patents by Inventor David S. Weinstein

David S. Weinstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20240002364
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: CHUNJIAN LIU, MICHAEL G. YANG, ZILI XIAO, LING CHEN, RYAN M. MOSLIN, JOHN S. TOKARSKI, DAVID S. WEINSTEIN, STEPHEN T. WROBLESKI
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11787779
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: October 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS
    Publication number: 20230167092
    Abstract: There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating inflammatory and autoimmune diseases or disorders.
    Type: Application
    Filed: April 27, 2021
    Publication date: June 1, 2023
    Inventors: Chunjian Liu, James Lin, David S. Weinstein
  • PRODRUGS IN THE MODULATION OF INTERLEUKIN
    Publication number: 20230167082
    Abstract: There are disclosed prodrugs of the compounds of the formula. The prodrugs are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: July 14, 2020
    Publication date: June 1, 2023
    Inventors: Ryan M. Moslin, David S. Weinstein, Thangeswaran Ramar, Murugaiah Andappan Murugaiah Subbaiah
  • Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 11597721
    Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 7, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zili Xiao, Michael G. Yang, Chunjian C. Liu, Trevor C. Sherwood, John L. Gilmore, David S. Weinstein
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20220356180
    Abstract: Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 29, 2021
    Publication date: November 10, 2022
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Zhang, Qingjie Liu
  • Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-? modulators
    Patent number: 11299494
    Abstract: Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: April 12, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, John V. Duncia, Steven H. Spergel
  • IMIDAZOPYRIDAZINE COMPOUNDS
    Publication number: 20210323966
    Abstract: Compounds of formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 16, 2017
    Publication date: October 21, 2021
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: David S. WEINSTEIN, John V. DUNCIA, Steven H. SPERGEL
  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20210253554
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 19, 2021
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 11021475
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11021462
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • HETEROCYCLIC COMPOUNDS COMPRISING PYRIDINE USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20210032220
    Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Zili Xiao, Michael G. Yang, Chunjian C. Liu, Trevor C. Sherwood, John L. Gilmore, David S. Weinstein
  • Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 10781215
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 22, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, David S. Weinstein, Michael G. Yang
  • AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20200071315
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Amit Kumar, Douglas G. Batt, Shuqun Lin, Chunjian Liu, Steven H. Spergel, Yanlei Yanlei, Qingjie Liu
  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10479793
    Abstract: Compounds of formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: November 19, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: David S. Weinstein, Ryan M. Moslin, Yanlei Zhang, Daniel S. Gardner, Joseph B. Santella, Charles M. Langevine, Sylwia Stachura
  • HETEROBICYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20190322672
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 24, 2019
    Inventors: Stephen T. Wrobleski, David S. Weinstein, Michael G. Yang
  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20190152948
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 23, 2019
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein
  • Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of IL-12, IL-23 and/or IFN alpha responses
    Patent number: 10294256
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: May 21, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Yang, Zili Xiao, John V. Duncia, David S. Weinstein
  • Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN-? responses
    Patent number: 10273237
    Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: April 30, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, James Lin, Ryan M. Moslin, David S. Weinstein, John S. Tokarski
  • Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: RE47929
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: April 7, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, David S. Weinstein, Stephen T. Wrobleski, John S. Tokarski, Shuqun Lin, Steven H. Spergel, Yanlei Zhang